Justin C Brown1, Kathryn H Schmitz. 1. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: Clinical guidelines recommend that oncologists prescribe exercise to their patients with colorectal cancer (CRC). However, 84% of oncologists do not prescribe exercise, citing concerns of safety and feasibility. Data are inadequate regarding the proportion of CRC survivors that could be safely prescribed with the dose of exercise recommended by the American College of Sports Medicine (ACSM), American Cancer Society (ACS), or National Comprehensive Cancer Network (NCCN) in an unsupervised setting. METHODS: We reviewed published guidelines for exercise prescription among cancer survivors and extracted health factors that may necessitate referral to trained personnel (physical therapist or exercise professional) for an individualized exercise program or supervision of exercise as recommended by the ACSM/ACS/NCCN. We applied these health factors to a cohort of nonmetastatic CRC survivors 6 months after completing curative care. The primary outcome was the proportion of CRC survivors to whom oncologists could prescribe unsupervised exercise at the dose recommended by the ACSM/ACS/NCCN. RESULTS: Among 351 CRC survivors, 6 months after curative care, 21%-42% of patients could be prescribed with the dose of exercise recommended by the ACSM/ACS/NCCN. Estimates varied as a function of the inclusion or exclusion of several prevalent comorbid health conditions including hypertension, diabetes, arthritis, obesity, and hyperlipidemia. CONCLUSIONS: Our data are consistent with the clinical observation that a large proportion of CRC survivors may be unable to participate in unsupervised exercise 6 months after curative care. These data underscore the need for continued research to clarify the safety and feasibility of prescribing exercise to CRC survivors.
PURPOSE: Clinical guidelines recommend that oncologists prescribe exercise to their patients with colorectal cancer (CRC). However, 84% of oncologists do not prescribe exercise, citing concerns of safety and feasibility. Data are inadequate regarding the proportion of CRC survivors that could be safely prescribed with the dose of exercise recommended by the American College of Sports Medicine (ACSM), American Cancer Society (ACS), or National Comprehensive Cancer Network (NCCN) in an unsupervised setting. METHODS: We reviewed published guidelines for exercise prescription among cancer survivors and extracted health factors that may necessitate referral to trained personnel (physical therapist or exercise professional) for an individualized exercise program or supervision of exercise as recommended by the ACSM/ACS/NCCN. We applied these health factors to a cohort of nonmetastatic CRC survivors 6 months after completing curative care. The primary outcome was the proportion of CRC survivors to whom oncologists could prescribe unsupervised exercise at the dose recommended by the ACSM/ACS/NCCN. RESULTS: Among 351 CRC survivors, 6 months after curative care, 21%-42% of patients could be prescribed with the dose of exercise recommended by the ACSM/ACS/NCCN. Estimates varied as a function of the inclusion or exclusion of several prevalent comorbid health conditions including hypertension, diabetes, arthritis, obesity, and hyperlipidemia. CONCLUSIONS: Our data are consistent with the clinical observation that a large proportion of CRC survivors may be unable to participate in unsupervised exercise 6 months after curative care. These data underscore the need for continued research to clarify the safety and feasibility of prescribing exercise to CRC survivors.
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Thomas A Wadden; Sheri Volger; David B Sarwer; Marion L Vetter; Adam G Tsai; Robert I Berkowitz; Shiriki Kumanyika; Kathryn H Schmitz; Lisa K Diewald; Ronald Barg; Jesse Chittams; Reneé H Moore Journal: N Engl J Med Date: 2011-11-14 Impact factor: 91.245
Authors: N J van Leersum; M L G Janssen-Heijnen; M W J M Wouters; H J T Rutten; J W Coebergh; R A E M Tollenaar; V E P P Lemmens Journal: Int J Cancer Date: 2012-11-05 Impact factor: 7.396
Authors: William L Read; Ryan M Tierney; Nathan C Page; Irene Costas; Ramaswamy Govindan; Edward L J Spitznagel; Jay F Piccirillo Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Clin Colorectal Cancer Date: 2017-06-17 Impact factor: 4.481
Authors: Brian P Chen; Rashami Awasthi; Shane N Sweet; Enrico M Minnella; Andreas Bergdahl; Daniel Santa Mina; Francesco Carli; Celena Scheede-Bergdahl Journal: Support Care Cancer Date: 2016-08-18 Impact factor: 3.603
Authors: Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2016-03-10 Impact factor: 2.226
Authors: Xiaochen Zhang; Ashley F Haggerty; Justin C Brown; Robert Giuntoli; Lilie Lin; Fiona Simpkins; Lorraine T Dean; Emily Ko; Mark A Morgan; Kathryn H Schmitz Journal: Gynecol Oncol Date: 2015-08-22 Impact factor: 5.482